戈沙妥珠单抗治疗中国复发/转移性宫颈癌患者:2期EVER-132-003篮子研究(NCT05119907)结果
开放标签2期EVER-132-003研究宫颈癌队列纳入40例经治中国复发/转移性宫颈癌患者,接受戈沙妥珠单抗10 mg/kg第1、8天给药、21天为一周期。中位随访9.6个月时,研究者评估的客观缓解率为43%(95%CI 27-59),中位缓解持续时间9.2个月,中位无进展生存期7.1个月。
要点
- 经治中国复发/转移性宫颈癌患者接受戈沙妥珠单抗的客观缓解率为43%(95%CI 27-59)。
- 中位随访9.6个月时,中位缓解持续时间9.2个月,中位无进展生存期7.1个月。
- ≥3级治疗中出现的不良事件发生于25例(63%)患者,最常见为中性粒细胞减少17例(43%)。
核心结论
- 单药戈沙妥珠单抗在经治中国复发/转移性宫颈癌患者及既往接受过免疫治疗的患者中显示出有前景的抗肿瘤活性。
- 不良事件可控,与戈沙妥珠单抗已知的安全性特征一致。
研究设计与样本
- 开放标签2期EVER-132-003研究(NCT05119907)宫颈癌队列。
- 纳入40例经治中国复发/转移性宫颈癌患者,接受戈沙妥珠单抗10 mg/kg静脉给药,21天周期第1天和第8天给药。
- 主要终点为研究者评估的客观缓解率,次要终点包括研究者评估的缓解持续时间和无进展生存期以及总生存期和安全性。
主要发现
- 40例入组患者中位年龄54岁,既往因复发/转移性疾病接受中位2线(范围1-5)全身治疗,68%既往接受过免疫治疗。
- 全分析集中位随访9.6个月时,客观缓解率为43%(95%CI 27-59),中位缓解持续时间9.2(95%CI 4.6-11.7)个月,中位无进展生存期7.1(95%CI 4.2-8.4)个月。
- 既往接受过免疫治疗的患者中观察到相似疗效:客观缓解率48%,中位缓解持续时间9.5个月。
- Trop-2表达的探索性分析显示与戈沙妥珠单抗疗效相关性有限。
- ≥3级治疗中出现的不良事件发生于25例(63%)患者,最常见为中性粒细胞减少17例(43%)、白细胞减少15例(38%)和贫血8例(20%);3例(8%)患者因治疗中出现的不良事件停用戈沙妥珠单抗,无治疗中出现的不良事件导致死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for metastatic cervical cancer is chemotherapy plus immunotherapy in first line and antibody-drug conjugates in second line. Limited treatment options exist after progression on first-line therapy, particularly after immunotherapy. METHODS: In the cervical cancer cohort of open-label, phase 2 EVER-132-003 (NCT05119907) study, Chinese patients with previously treated recurrent/metastatic cervical cancer received sacituzumab govitecan (SG) 10 mg/kg intravenously on days 1 and 8 of 21-day cycles. Primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed duration of response (DOR) and progression-free survival (PFS) as well as overall survival and safety. RESULTS: For the 40 patients enrolled, median age was 54 years. Patients received median two (range, 1-5) prior systemic treatments for recurrent/metastatic disease; 68 % received prior immunotherapy. In the full analysis set, at 9.6 months' median follow-up, ORR was 43 % (95 % CI, 27-59) and median DOR 9.2 (95 % CI, 4.6-11.7) months. Median PFS was 7.1 (95 % CI, 4.2-8.4) months. Similar efficacy was observed in patients previously treated with immunotherapy (ORR 48 %, median DOR 9.5 months). Exploratory analysis of Trop-2 expression showed limited correlation with SG efficacy. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 25 (63 %) patients, most frequently neutropenia (17 [43 %]), leukopenia (15 [38 %]), and anemia (8 [20 %]). Overall, 3 (8 %) patients discontinued SG due to TEAEs. No TEAEs led to death. CONCLUSIONS: Single-agent SG demonstrated promising antitumor activity in pretreated Chinese patients with recurrent/metastatic cervical cancer and in patients previously treated with immunotherapy. AEs were manageable and consistent with known SG safety profile.
引用
- An J, Li G, Zhang Y, et al. Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecol Oncol. 2025. PMID: 40972504. doi:10.1016/j.ygyno.2025.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。